Povidone-iodine

Generic Name: Povidone-iodine

Brand Names: Betadine, Kenalog, Marbeta, Marcaine, P-Care M, P-Care MG, P-care, P-care X, Summer's Eve Medicated

Drug Type: Small Molecule

CAS Number: 25655-41-8

Unique Ingredient Identifier: 85H0HZU99M

Background: Povidone-iodine is a stable chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine. It contains from 9.0% to 12.0% available iodine, calculated on a dry basis. This unique complex was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A. Shelanski and M. V. Shelanski. During in vitro testing to demonstrate anti-bacterial activity it was found that the complex was less toxic in mice than tincture of iodine. Human clinical trials showed the product to be superior to other iodine formulations. Povidone-iodine was immediately marketed, and has since become the universally preferred iodine antiseptic.

Indication: For topical application in the treatment and prevention of infection in wounds.

Associated Conditions: Skin Infections

Associated Therapies: Skin disinfection, Antiseptic skin preparation therapy, Irrigation of the ocular surface therapy, Prepping of the periocular region

Clinical Trials

COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients

Phase 2

Completed

Conditions: COVID-19
SARS-CoV 2

Interventions: Drug: Povidone-Iodine Nasal Spray and Gargle

First Posted Date: 2020-04-28

Last Posted Date: 2022-12-02

Lead Sponsor: Nikita Gupta

Target Recruit Count: 98

Registration Number: NCT04364802

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: Povidone-Iodine 2%
Drug: Povidone-Iodine 0.5%
Drug: Isotonic saline 0.9%

First Posted Date: 2020-04-15

Last Posted Date: 2021-10-21

Lead Sponsor: Stanford University

Target Recruit Count: 47

Registration Number: NCT04347954

Locations: 🇺🇸
Stanford Health Care, Stanford, California, United States

Povidone-Iodine Rinses as an Adjuvant Therapy Post-Operatively

Not Applicable

Conditions: Chronic Rhinosinusitis (Diagnosis)

Interventions: Drug: Placebos
Drug: Povidone-Iodine

First Posted Date: 2020-02-20

Last Posted Date: 2020-02-20

Lead Sponsor: St. Paul's Hospital, Canada

Target Recruit Count: 100

Registration Number: NCT04278950

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

Phase 2

Conditions: Warts

Interventions: Drug: VBP-245
Drug: Placebo Gel (no Povidone-Iodine)

First Posted Date: 2020-02-05

Last Posted Date: 2021-04-01

Lead Sponsor: Veloce BioPharma LLC

Target Recruit Count: 90

Registration Number: NCT04253912

Locations: 🇺🇸
Veloce BioPharma Clinical Trial Site, Lynchburg, Virginia, United States

Chlorhexidine and/or Betadine Prep in Pediatric Arm Surgery Following Trauma

Phase 4

Terminated

Conditions: Arm Fracture
Surgical Site Infection

Interventions: Other: Chlorhexidine
Other: Betadine

First Posted Date: 2020-01-13

Last Posted Date: 2024-09-27

Lead Sponsor: Mark Seeley

Target Recruit Count: 10

Registration Number: NCT04225065

Locations: 🇺🇸
Geisinger Woodbine, Danville, Pennsylvania, United States

Glenohumeral Cortisone Injection

Phase 2

Completed

Conditions: Humeral Fractures

Interventions: Drug: Lidocaine
Drug: kenalog

First Posted Date: 2020-01-02

Last Posted Date: 2023-09-26

Lead Sponsor: University of Washington

Target Recruit Count: 9

Registration Number: NCT04216017

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Nasal Decolonization of Dialysis Patients Noses

Phase 4

Active, not recruiting

Conditions: Staphylococcus Aureus Infection

Interventions: Drug: Povidone-Iodine Topical Ointment
Other: Standard Care

First Posted Date: 2019-12-24

Last Posted Date: 2023-06-28

Lead Sponsor: Marin L. Schweizer, PhD

Target Recruit Count: 302

Registration Number: NCT04210505

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Emory Healthcare, Atlanta, Georgia, United States

and more 2 locations

Modified Treatment for Epidemic Keratoconjunctivitis (EKC)

Not Applicable

Completed

Conditions: Symptoms and Signs

Interventions: Drug: Normal Saline Flush
Drug: Povidone-Iodine

First Posted Date: 2019-11-20

Last Posted Date: 2019-11-20

Lead Sponsor: Minia University

Target Recruit Count: 350

Registration Number: NCT04169919

Nasal Decolonization for Orthopedic Trauma Patients

Phase 4

Completed

Conditions: Surgical Site Infection

Interventions: Drug: intranasal povidone-iodine

First Posted Date: 2019-10-31

Last Posted Date: 2023-06-28

Lead Sponsor: University of Iowa

Target Recruit Count: 65

Registration Number: NCT04146116

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial

Phase 4

Terminated

Conditions: Full Thickness Rotator Cuff Tear
Rotator Cuff Tendinitis

Interventions: Drug: Marcaine (placebo)
Drug: Ketorolac
Drug: Kenalog

First Posted Date: 2019-10-04

Last Posted Date: 2023-12-14

Lead Sponsor: Michael Khazzam

Target Recruit Count: 82

Registration Number: NCT04115644

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
John Hopkins Shoulder & Sports Medicine, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy